Chord Energy (CHRD)
NASDAQEnergyOil & Gas Exploration & ProductionSnapshot 2026-10-29
$153.63-0.28%
Close 2026-10-29 · 1-day change
NASDAQEnergyOil & Gas Exploration & ProductionSnapshot 2026-10-29
Research Workspace
Put CHRD beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Oil & Gas Exploration & Production is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue is growing steadily — about 19% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 21%.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskMostly healthy — no soft spokes
CHRD’s case rests on strong financial performance and generating approximately $3.0B Adjusted EBITDA in FY26. Recent quarterly earnings shifted from a beat to a miss, with Q2 FY2026 non-GAAP EPS missing by 3.6%. CHRD trades at 11× P/E versus a 19× peer median. The price reflects less growth than our forecast, though the peer comparison is a weak guide. The next-quarter miss probability is 36%, and capital-spending discipline faces conflicting signals from the Marcellus sale. Peer multiples imply a price about 24% above where it trades; our read remains intact. This read is provisional.
Trailing returns as of 2026-10-29. CHRD is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 18 analysts currently covering CHRD (as of Oct 2026).
Based on 8 Wall Street analysts offering 12-month price targets for CHRD in the last 4 months.
Continue this research
Compare CHRD with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CHRD Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Oil & Gas Exploration & Production — fair value, gap to price, and forward P/E.
Compare the value case
Put CHRD next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Generate approximately $3.0B Adjusted EBITDA in FY26
Positive outlook supports EBITDA generation objective.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $153.63
The last 12 months of price, then the range of analyst 12-month targets from today’s $153.63.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Generate approximately $3.0B Adjusted EBITDA in FY26
Price target increase suggests positive outlook on EBITDA generation.
Threatens: Maintain disciplined capital expenditures at $1.4B for FY26
Price target cut indicates potential capital allocation issues.
Advances: Maintain disciplined capital expenditures at $1.4B for FY26
Sale improves capital allocation and focus on core operations.
Advances: Generate approximately $1.3B Adjusted Free Cash Flow in FY26
Q2 results support FCF growth and buyback strategy.
Advances: Generate approximately $1.3B Adjusted Free Cash Flow in FY26
Strong Q2 results support free cash flow generation objective.
Advances: Achieve $3.1B of Adjusted EBITDA in FY26
Earnings beat supports EBITDA growth objective.
Advances: Achieve $3.1B of Adjusted EBITDA in FY26
Raised output guidance enhances EBITDA outlook.